The strategic alliance between Roche and reMYND is nominated for a Scrip Award

The strategic Alliance between Roche and reMYND to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients is nominated for the Scrip Award “Best Partnership Alliance”. The winners will be announced in London on November 3rd, 2011.

reMYND’s grant from the Michael J Fox Foundation in SciBX

The Science-Business eXchange (SciBX, a publication by the makers of BioCentury and Nature) devoted in its recent publication an article to the role the Michael J Fox Foundation for Parkinson’s Research has been playing in the development of PD therapeutics.

IWT helps to accelerate reMYND’s Diabetes program with a grant of 1.48 million EUR for 2011-2012

reMYND NV today announced that it has received a grant of 1.48 million EUR from IWT, the Flemish agency for Innovation by Science and Technology, to accelerate its Diabetes program.

reMYND’s CRO receives governmental grant for a continued innovation of its offering

On its Board Meeting of April 28th 2011, the governmental Agency for Innovation by Science and Technology (IWT) has approved a grant to reMYND’s Contract Research Organization (CRO) for the ‘Evaluation of candidate behavioral and synaptic markers in tra

reMYND's CRO announces quarterly digital Newsletter

With our quarterly Newsletter, we intend to provide our clients and contacts with some additional thoughts for the preclinical in-vivo testing of their experimental Alzheimer therapies. The one-pager will highlight particular aspects of our Services Offering, provide updates on new models and rea